Featured Video
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
3:00 MIN
- CIDP
- MMN
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Our Experts
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
- CIDP
- MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
- CIDP
- GBS
Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
- CIDP
- GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
- MMN
Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California.
Back to Top